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INTRODUCTION
Neuroendocrine tumours (NETs) are neoplasms mainly originating from the gastro-enteropancreatic area (67.5%) and the bronchial tree (25.3%) [1] . According to the World Health Organization (WHO) criteria [2] , lung tumours with neuroendocrine morphology include four major categories of morphologically identifiable NETs from low (typical carcinoid, TC) and intermediate grade (atypical carcinoid, AC), to high grade tumours (large cell neuroendocrine carcinoma, LCNEC, and small cell carcinoma, SCLC) that exhibit considerably different histological and clinical characteristics [3] . TCs are generally benign tumours with an excellent prognosis after radical surgery (up to 98% of 5-year survival). Regional lymph node or distant metastases are detected or develop over time in about 10% of cases. ACs are histologically similar to TCs (though with a higher mitotic count and/or necrosis), but up to 48% of cases present lymph node or distant metastases at diagnosis; their prognosis has been related to several predictive factors [4] . LCNEC and SCLC, both highly aggressive tumours, have overlapping histopathological features (except for the cell size) and clinical behaviour [5, 6] .
Several neuroendocrine markers and hormonal receptors have been described in NETs having diagnostic, prognostic and also therapeutic implications. Among the latter, somatostatin receptors (SSTRs) are a family of five widely distributed G-protein-coupled receptors, that mediate different intracellular signalling pathways involved in cell proliferation, differentiation and angiogenesis [7] . Synthetic somatostatin analogs have been produced, being octreotide and lanreotide those most widely employed in the clinical practice. Their high receptor binding affinity (especially for SSTR2, SSTR3 and SSTR5) [8] is the basis for both diagnostic (i.e. scintigraphy or PET scans) and therapeutic procedure. Novel ligands with enhanced and/or wide receptor affinity (for example multivalent ligands, such as pasireotide) are currently under validation [9] .
Differently from gastro-entero-pancreatic NETs, the management of pulmonary NET affected patients is less standardized apart from surgical resection [10] , chemo-radiotherapy or liver metastasis embolization [11] . In particular, diagnostic and therapeutic guidelines for somatostatin analog use in lung NETs are not available and their association with standard chemotherapy is still debated [12] . This may in part be due to the incomplete knowledge on SSTR(s) expression and distribution in pulmonary NETs: data so far generated have generally been based on polymerase chain reaction, in situ hybridization, autoradiography or immunohistochemistry analyses of limited and/or heterogeneous neuroendocrine tumour series, accounting for less than 100 reported cases (most of them being carcinoids) [13] [14] [15] [16] [17] [18] [19] [20] . Recently, we reported a strong correlation between specific cellular patterns of SSTR2 immunostaining and in vivo scintigraphic data in a large series of gastro-entero-pancreatic and few lung neuroendocrine tumours [21] , indicating that immunohistochemistry may correctly define the SSTR protein distribution in these neoplasms.
Since in the common clinical practice the presence of one or more SSTR subtypes in a given tumour (either by means of positive somatostatin analog-based nuclear imaging or SSTR immunohistochemistry) should be demonstrated to justify patient's selection for somatostatin analog therapy, this study was aimed at correlating the SSTR expression profile of a large series of "clinically aggressive" pulmonary neuroendocrine tumours (thus excluding conventional nonmetastatizing typical carcinoids) with complete clinical and pathological data in order to substantiate the rationale for somatostatin analog clinical use in these tumour categories.
MATERIALS AND METHODS

Case series
In years 1989-2007, a total of 883 cases of surgically resected NETs of the lung were on record in the pathology files of the Universities of Turin and Parma and at the IEO of Milan (467, 188 and 228 cases, respectively). Among them, a series of 218 "clinically aggressive" lesions was collected (129 cases from Turin, 40 from Parma and 49 from Milan) that included 24 TC with metastases at the time of diagnosis (TC mets) [all but one in regional lymph nodes, the remaining case to the liver], 73 AC, 60 LCNEC and 61 surgically resected SCLC. For all cases, from one to six representative haematoxylin and eosin sections were available for review and re-classification according to the WHO scheme [2] . A control group of 41 TC free from node and distant metastases at the time of diagnosis and during available follow up (control TC) were collected from the files of the University of Turin, in the same period.
Pathological material corresponded to primary lung samples in all but 14 cases, where lymph node metastases only were analyzed. For all cases, clinicopathologic information including sex, age, tumour location, surgical procedure, parenchymal location, primary tumour size, Ki-67 labeling index (expressed as the percentage of positive cells in highest labeling areas), nodal status, stage, follow up and site of distant metastases were collected. All cases were anonymized by a pathology staff member not involved in the study. Clinical data were compared and analysed through coded data, only. The study was approved by the institutional review board of the Hospital.
In 28 cases, [
111 In-DTPA 0 ]-octreotide scintigraphic data (Octreoscan) were available for correlation analyses (eight of these cases had been included in a previous report [19] ). Somatostatin receptor scintigraphy findings were scored into four groups, according to Kwekkeboom et al [22] criteria.
Finally, eight cases were submitted to somatostatin analog based therapy (intramuscular injection of octreotide for six months, 20 mg/28 days, and/or 90Y-DOTATOC radiometabolic therapy, either alone or in combination with chemotherapeutic agents) and information on response to treatment (in terms of partial remission, stable disease or progressive disease) were available.
SSTR immunohistochemistry
Immunohistochemistry was performed using polyclonal antibodies against SSTR type 2A,
(diluted 1/3000, BioTrend Cologne, Germany), type 3 (diluted 1/1000, AbCam, Cambridge, UK) and type 5 (diluted 1/500, AbCam) according to previously described protocols [21] . The specificity of the reactions was validated in parallel control sections stained by omitting the primary antibodies for each immunohistochemical run. Pancreatic islets served as positive controls.
The efficiency of all three antibodies was tested in a pilot series of 56 randomly selected cases. SSTR5 immunohistochemistry in positive controls and test sections proved unsatisfactory in terms of both intensity and background, and was therefore not investigated further in the whole series.
SSTR2A and SSTR3 staining evaluation
Immunohistochemical stains for SSTR type 2A and type 3 were scored as recently proposed by our group [21] . This semi-quantitative scoring system applies better for SSTR2A and takes into consideration both the subcellular localization and the extent of the staining, as follows: score 0:
absence of immunoreactivity; score 1: pure cytoplasmic immunoreactivity, either focal or diffuse; score 2: membranous reactivity in less than 50% of tumour cells, irrespective of the presence of cytoplasmic staining; score 3: circumferential membranous reactivity in more than 50% of tumour cells, irrespective of the presence of cytoplasmic staining.
SSTR3 immunohistochemical reaction showed a diffuse cytoplasmic staining, with weak membrane reinforcement in some cases, either of control or of test series. Reactions were evaluated in a four-tier scoring system, from 0 (no reaction) to 3, according to the intensity of cytoplasmic staining and irrespective of the extent of positive neoplastic cells.
Statistical analysis
For statistical purposes, immunohistochemical scores 2 and 3 of both SSTR type 2A and type 3 antibody were grouped together and considered positive, while scores 0 and 1 were considered negative. Chi-square and One-way ANOVA tests were used to compare clinicopathologic data and SSTR(s) distribution among different tumour categories, setting the level of statistical significance of p=0.05. Concondance analysis between immunohistochemical results and scintigraphy data was investigated using a contingency table analysis. Univariate survival analysis among different tumour categories and with respect to SSTR(s) expression was based on the Kaplan-Meier product limit estimate of overall survival distribution. Unadjusted differences between survival curves were tested using the LogRank test.
RESULTS
Clinicopathologic findings
Clinicopathologic features of the 218 cases of "clinically aggressive" lung NETs are summarized in Table 1 .
Male predominance was observed in high grade carcinomas as opposed to low and intermediate grade tumours (p<0.0001), whereas no significant difference among the different tumour types was observed in terms of patient age, tumour location and surgical procedure applied.
With respect to pulmonary location, a significant difference was observed among the four groups (p=0.02), being central location predominant in TC mets, as compared to AC and LCNEC which presented a more frequent peripheral onset, whereas SCLC were equally distributed among the two locations.
The mean primary tumour size significantly increased from TC mets to AC and poorly differentiated tumours (p=0.003), as well as the mean Ki-67 proliferative index (p<0.0001). The rate of nodal involvement at the time of diagnosis was 47%, 39% and 61% in AC, LCNEC and SCLC respectively, with no difference between N1 vs N2-3 location of positive lymph nodes.
Overall survival was strongly depending on tumour type (Figure 1 , p<0.0001) with no disease-related deaths for the metastatic TC group, and a mean overall survival of 122, 30 and 23 months for AC, LCNEC and SCLC, respectively.
With respect to the presence of ectopic peptide secretion, all cases were clinically nonfunctioning, except for two cases of AC with ectopic ACTH secretion in the presence of diabetes mellitus and metabolic disorders.
Immunohistochemical distribution of SSTR2A and SSTR3
All immunohistochemical reactions were analyzed independently by two observers (LR and MV) in one centre (Turin) according to the previously described scoring system. A satisfactory reproducibility was obtained in the vast majority of cases and the few discrepant cases were rescored at a multi-head microscope and a consensus was reached. SSTR2A staining pattern showed a strong membrane positivity in TC mets and AC groups as opposed to high grade carcinoma groups, in which membrane staining was found in focal areas or scattered cells only ( Figure 2A ). SSTR3
showed cytoplasmic reactivity with different staining intensity and only rare cases showed a membrane pattern of staining. SSTR types 2A and 3 distribution among the different tumour types is illustrated in Figure 2B . an overall agreement of 50%. The immunohistochemical presence of at least one receptor type was concordant with scintigraphy in 20/28 cases (71% of agreement), although with a marked loss of "specificity" (Table 3) .
With respect to biotherapy response, 8 cases, all but one affected by AC, received at the time of disease progression long-acting octreotide and/or therapy with radiolabeled octreotide, both associated or not to standard platinum-based chemotherapy. SSTR2A immunoreactivity correlated with response to treatment in all but one cases (7/8); among these, three patients had disease stabilization in the presence of SSTR2A expression, whereas the remaining four cases, completely lacking SSTR2A reactivity, had disease progression. The single discrepant case had disease progression in spite of SSTR2A immunohistochemical expression. Notably, octreotide scintigraphy correlated with somatostatin analog response in 50% of cases (4/8), only.
DISCUSSION
In the present study, we analyzed the tissue distribution of SSTR2A and SSTR3 in a large series of pulmonary neuroendocrine neoplasms consisting of low to intermediate grade tumours
with "clinically aggressive" features (i.e. lymph node or distant metastases) and high grade large cell or small cell carcinomas. Although the link between SSTR(s) expression and lung NETs management was already proposed [7, 23] , an extensive analysis of SSTR tissue distribution is missing, being data available for limited series, with heterogeneous techniques and mostly restricted to clinically benign carcinoids (usually not requiring further treatment) [13, 14, 18, 19] .
From the literature data, the current knowledge on SSTRs and lung NETs can be summarized as follows: i) lung NETs contain SSTR subtypes having an affinity to octreotide, namely types 2, 3 and 5, with a decreasing expression from low/intermediate to high grade tumours [23] ; ii) somatostatin receptor scintigraphy may be used to localize neuroendocrine tumours primary or secondary to the lung [24] , although its role is supported by limited literature data, most often biased by heterogeneous imaging modalities, small case series and unselected tumour types [25, 26] ; iii) biotherapies with somatostatin analogs are largely employed for advanced NETs of the gastro-entero-pancreatic tract, either alone or in combination with interferon or chemotherapeutic agents [12] , but in lung NETs the experience is restricted to limited clinical studies using somatostatin analogs as drugs [11, 27] or radionuclide vectors [28] . In summary, compared to gastro-entero-pancreatic NETs, the management of aggressive forms of lung NETs is not well clarified yet and the role of biotherapies is incompletely explored.
In this study, a complete map of SSTR type 2A and type 3 tissue distribution was provided in a large series of lung NETs including the whole spectrum of clinically aggressive forms (from metastatic typical carcinoids to small cell lung cancer).
Both SSTR types 2A and 3 had a decreased expression from low/intermediate to high grade tumours, as previously observed by our group in smaller series [18, 19] . Interestingly, in the group of low to intermediate grade tumours, SSTR2A was expressed at a significant higher frequency in metastatic TC as compared either to clinically benign control TCs, alone (p=0.004) or in coexpression with SSTR3 (p=0.04), either compared to the AC group. The Ki-67 index of TC with metastases was not different from that of non metastatic TC (data not shown), suggesting that the SSTR2A status rather than the proliferation fraction is related to metastatic propensity in lung carcinoids. Furthermore, a higher expression of intracellular molecules downstream to the SSTRs, such as mTOR and its effector p70S6K, was observed by our group in a series of metastatic TC as compared to non-metastatizing TC (manuscript in preparation), further supporting a biological diversity among these two subgroups. No data on the functional role of somatostatin receptors in favouring tumor metastases are present in the literature that might support this observation, that apparently contrasts with the decrease of somatostatin receptor expression in high gradefrequently metastatic -tumors and whose biological meaning would need further investigation.
Moreover, it should be underlined that our series of metastatic TC had an excellent prognosis since no patient (even the single case with liver metastases) is currently dead of the disease, thus confirming that nodal involvement in typical carcinoids is not significantly impacting on survival (aggiungere citazione Ferolla) and raising the question of the potential clinical benefit of postsurgical somatostatin analog therapy in asymptomatic patients.
When comparing the present immunohistochemical results with the prevalence data of positive octreotide scintigraphy in lung NETs available from the literature, a slightly higher percentage is reported for carcinoids (about 70% of primary tumours in one of the most recent and complete series -28 cases) [29] , while an exceedingly higher percentage is reported for SCLC, (up to 96% of primary tumours in a large, old series -100 cases) [30] . In the present series of 28 cases with available scintigraphy data, an overall 71% agreement between Octreoscan and immunohistochemistry was obtained. Major causes of discrepancy between these two methods include on the one hand false positive SSTRs scintigraphy related to necrotic areas or inflammation (often observed in SCLC) [19] , in the other the possible role of other SSTR subtypes than types 2A and 3 with high affinity for the currently used somatostatin analogues (namely SSTR5, not analyzed in this study for technical reason). Moreover, it should be speculated that immunohistochemistry may represent a less sensitive method as compared to somatostatin receptor scintigraphy because of heterogeneous SSTR distribution in tumour tissues or technical artifacts related to tissue fixation.
However, we strongly believe that speculating which method is more sensitive or specific is indeed useless. In contrast, we encourage the use of immunohistochemistry as a potentially useful adjunct to SSTR scintigraphy in lung NETs work-up.
Despite several cases in our series displayed an aggressive and fatal clinical course even in the group of low/intermediate grade tumours, only eight patients of the present series underwent biotherapy with somatostatin analogs, therefore limiting the possibility to test the possible value of somatostatin receptor immunohistochemistry to predict the clinical response to somatostatin analog therapy. This fact, rather than a limit of our investigation, represents the actual clinical picture and reflects the lack of robust trials validating the use of somatostatin analogs in advanced lung NETs.
In conclusion, our study describes SSTR(s) tissue localization in a very large series of aggressive lung NETs with clinicopathologic correlates, and strengthens the concept that the information on SSTR(s) expression at the tissue level in lung NET patients developing clinically aggressive disease may improve the clinical approach with somatostatin analog-based diagnostic and therapeutic procedures. "specificity"* 71% 57% 42% 
